과제정보
This study was performed according to the Declaration of Helsinki, and approved by the Ethics Committee of Shanghai Outdo Biotech Company (Protocol code: SHYJS-CP-1701002). The informed consent was obtained from all subjects involved in the study. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2022R1I1A1A01063460 and 2021R1A5A8029876 to Y.J.; 2023R1A2C3006220, 2022K2A9A1A06091879, and RS2023-00261370 to D.R. and K.T.H). Moreover, the study was also supported by an Inha University Research Grant to D.R. and a "GIST Research Institute (GRI) IIBR" grant funded by the GIST to D.R. in 2023.
참고문헌
- Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A and Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16, 589-604
- Park M, Moon B, Kim JH et al (2022) Downregulation of SETD5 suppresses the tumorigenicity of hepatocellular carcinoma cells. Mol Cells 45, 550-563
- Shin EC (2021) Cancer immunotherapy: special issue of BMB Reports in 2021. BMB Rep 54, 1
- Lee HO and Park WY (2017) Single-cell RNA-Seq unveils tumor microenvironment. BMB Rep 50, 283-284
- Jiang Y, Wei S, Koo JM et al (2023) Integrative evaluation of the clinical significance underlying protein arginine methyltransferases in hepatocellular carcinoma. Cancers (Basel) 15, 4183
- Jin HT, Jeong YH, Park HJ and Ha SJ (2011) Mechanism of T cell exhaustion in a chronic environment. BMB Rep 44, 217-231
- Lee YJ, Lee JB, Ha SJ and Kim HR (2021) Clinical perspectives to overcome acquired resistance to anti-programmed death-1 and anti-programmed death ligand-1 therapy in non-small cell lung cancer. Mol Cells 44, 363-373
- Zhang J, He T, Xue L and Guo H (2021) Senescent T cells: a potential biomarker and target for cancer therapy. EBio-Medicine 68, 103409
- Kasakovski D, Xu L and Li Y (2018) T cell senescence and CAR-T cell exhaustion in hematological malignancies. J Hematol Oncol 11, 91
- Chen Z, Guo Y, Zhao D et al (2021) Comprehensive analysis revealed that CDKN2A is a biomarker for immune infiltrates in multiple cancers. Front Cell Dev Biol 9, 808208
- Chae J, Park WS, Kim MJ et al (2018) Genomic characterization of clonal evolution during oropharyngeal carcinogenesis driven by human papillomavirus 16. BMB Rep 51, 584-589
- Patsoukis N, Sari D and Boussiotis VA (2012) PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle 11, 4305-4309
- Chen SC, Lo CM, Wang SH and Su EC (2019) RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. BMC Bioinformatics 20, 659
- Mo Z, Yu L, Cao Z, Hu H, Luo S and Zhang S (2020) Identification of a hypoxia-associated signature for lung adenocarcinoma. Front Genet 11, 647
- Zhao R, Choi BY, Lee MH, Bode AM and Dong Z (2016) Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer. EBioMedicine 8, 30-39
- Kreuger IZM, Slieker RC, van Groningen T and van Doorn R (2023) Therapeutic strategies for targeting CDKN2A loss in melanoma. J Invest Dermatol 143, 18-25 e11
- Chen X, Yu X and Shen E (2019) Overexpression of CDKN2B is involved in poor gastric cancer prognosis. J Cell Biochem 120, 19825-19831
- Khemlina G, Ikeda S and Kurzrock R (2017) The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer 16, 149
- Luo JP, Wang J and Huang JH (2021) CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep 41, BSR20211103
- Zhou Y, Wang XB, Qiu XP, Shuai Z, Wang C and Zheng F (2018) CDKN2A promoter methylation and hepatocellular carcinoma risk: a meta-analysis. Clin Res Hepatol Gastroenterol 42, 529-541
- Erickson S, Sangfelt O, Heyman M, Castro J, Einhorn S and Grander D (1998) Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence. Oncogene 17, 595-602
- Seimiya T, Otsuka M and Fujishiro M (2023) Overcoming T-cell exhaustion: new therapeutic targets in HCC immunotherapy. Hepatology 78, 1009-1011
- Barsch M, Salie H, Schlaak AE et al (2022) T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J Hepatol 77, 397-409
- Huff WX, Bam M, Shireman JM et al (2021) Aging- and tumor-mediated increase in CD8(+)CD28(-) T cells might impose a strong barrier to success of immunotherapy in glioblastoma. Immunohorizons 5, 395-409
- Ferrara R, Naigeon M, Auclin E et al (2021) Circulating T-cell immunosenescence in patients with advanced non-small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy. Clin Cancer Res 27, 492-503
- Suen H, Brown R, Yang S et al (2016) Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 30, 1716-1724
- Song Y, Wang B, Song R et al (2018) T-cell Immunoglobulin and ITIM domain contributes to CD8(+) T-cell immunosenescence. Aging Cell 17, e12716
- Roessler S, Jia HL, Budhu A et al (2010) A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70, 10202-10212
- Lamb JR, Zhang C, Xie T et al (2011) Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS One 6, e20090
- Lim HY, Sohn I, Deng S et al (2013) Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. Ann Surg Oncol 20, 3747-3753
- Zheng C, Zheng L, Yoo JK et al (2017) Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342-1356 e1316